FibroGen Inc (FGEN): A Technical Analysis

FGEN has 36-month beta value of 0.82. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”

The public float for FGEN is 92.61M, and currently, short sellers hold a 7.47% ratio of that float. The average trading volume of FGEN on May 15, 2024 was 2.25M shares.

FGEN) stock’s latest price update

FibroGen Inc (NASDAQ: FGEN)’s stock price has soared by 3.81 in relation to previous closing price of 1.18. Nevertheless, the company has seen a gain of 8.41% in its stock price over the last five trading days. Seeking Alpha reported 2024-05-06 that FibroGen, Inc. (NASDAQ:FGEN ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants David DeLucia – VP, Corporate FP&A and IR Thane Wettig – CEO Deyaa Adib – CMO Juan Graham – CFO Chris Chung – SVP, China Operations Conference Call Participants Andy Hsieh – William Blair Paul Choi – Goldman Sachs Operator Good day and thank you for standing by. Welcome to the FibroGen’s First Quarter 2024 Earnings Conference Call.

FGEN’s Market Performance

FibroGen Inc (FGEN) has experienced a 8.41% rise in stock performance for the past week, with a -5.77% drop in the past month, and a -45.56% drop in the past quarter. The volatility ratio for the week is 13.10%, and the volatility levels for the past 30 days are at 13.39% for FGEN. The simple moving average for the last 20 days is 6.87% for FGEN’s stock, with a simple moving average of 3.01% for the last 200 days.

Analysts’ Opinion of FGEN

Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.

FGEN Trading at -24.41% from the 50-Day Moving Average

After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.71% of loss for the given period.

Volatility was left at 13.39%, however, over the last 30 days, the volatility rate increased by 13.10%, as shares sank -5.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.56% lower at present.

During the last 5 trading sessions, FGEN rose by +6.64%, which changed the moving average for the period of 200-days by -41.50% in comparison to the 20-day moving average, which settled at $1.1430. In addition, FibroGen Inc saw 38.22% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at FGEN starting from Wettig Thane, who purchase 50,000 shares at the price of $1.91 back on Mar 07 ’24. After this action, Wettig Thane now owns 470,178 shares of FibroGen Inc, valued at $95,470 using the latest closing price.

Henderson Jeffrey William, the Director of FibroGen Inc, sale 2,000 shares at $1.03 during a trade that took place back on Sep 01 ’23, which means that Henderson Jeffrey William is holding 28,866 shares at $2,060 based on the most recent closing price.

Stock Fundamentals for FGEN

Current profitability levels for the company are sitting at:

  • -1.41 for the present operating margin
  • 0.75 for the gross margin

The net margin for FibroGen Inc stands at -1.44. The total capital return value is set at -1.4. Equity return is now at value -42790.17, with -53.17 for asset returns.

Based on FibroGen Inc (FGEN), the company’s capital structure generated -0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -2.57. The debt to equity ratio resting at -0.47. The interest coverage ratio of the stock is -13.04.

Currently, EBITDA for the company is -259.28 million with net debt to EBITDA at -0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The receivables turnover for the company is 2.55for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.

Conclusion

To put it simply, FibroGen Inc (FGEN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts